Post-transcriptional RNA modification plays an important role in biological processes. For example, adenosines to nosiness or A-to-I editing are most abundant in the central nervous system (CNS) and essential for normal CNS development. Presently, the available reagents for detection, quantitation, or immunoprecipitation of modified RNA are extremely limited. Rockland Immunochemicals is collaborating with Aptagen to develop synthetic antibodies for detection and quantitation of modified RNAs. In Phase I, as a proof-of-principle, high-affinity and target-specific aptamers and aptamer-based detection assays for inosine and N6- methyladenosine containing RNA will be developed. In Phase II, aptamer reagents and assays to more than 60 RNA modifications known in eukrayotes will be developed. These affinity reagents will be used in microarrays to profile RNA modifications in different mouse CNS disorder models.

Public Health Relevance

As a result of this proposed project, a comprehensive set of affinity reagents for detection and quantification of modified RNA will be developed. Such reagents will enable the scientific community to effectively explore the role of RNA modification in biological development.

Agency
National Institute of Health (NIH)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43DA038982-01
Application #
8841555
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Bough, Kristopher J
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Rockland Immunochemicals, Inc.
Department
Type
DUNS #
City
Pottstown
State
PA
Country
United States
Zip Code
19464